Healthy blood clotting is crucial to maintain a healthy circulatory system. Conditions that increase your risk for dangerous blood clots include smoking, sedentary lifestyle, diabetes, obesity, family history of blood clots, cardiovascular disease, cancer and flying on airplanes. Blood clots account for 80% of strokes because they impede circulation of blood and nutrients to the brain anywhere in the body where they might become a problem. Blood clots in the back of the legs is called deep vein thrombosis, and can be extremely painful. If the blood clots dislodge and begin circulating through the blood stream, they can travel to the lungs. If that happens it’s called a pulmonary embolus.
NattoPine® is the only product with the combination and dose of ingredients shown in a clinical trial to promote healthy blood clotting and circulation. None of the participants taking NattoPine’s ingredients had blood clots form that could cause dangerous deep vein thrombosis, while 7.6% of people not taking the nutrient combination had potentially dangerous blood clots form. In other words, 100% of people taking NattoPine’s formula maintained healthy circulation. And compared to those not taking the nutrients, people taking nattokinase and pine bark extract had a 27% decrease in leg swelling (edema).
Nutrients shown in a clinical trial promote healthy
blood clotting and circulation
Nutrients shown in a clinical trial promote healthy blood clotting and circulation
Customers Share Their NattoPine Stories
Why NattoPine Dissolves the Competition
**Nattokinase is an extract from a Natto, a Japanese food from fermented soybeans. Nattokinase promotes healthy blood clotting by preventing and breaking up clots. NattoPine contains the highest dose of nattokinse of any product. NattoPine also contains powerful antioxidants from pine bark extract to protect blood vessels from damaging free radicals.
NattoPine’s ingredients were shown in a clinical trial to reduce the risk of deep vein thrombosis by and leg swelling. In the clinical trial nearly 10% of people not taking the nattokinase and pine bark extract combination experienced a deep vein thrombosis versus none of those taking the dietary supplement. In other words, blood clots were prevented in 100% of people taking NattoPine’s formula. Those taking nattokinase and pine bark extract also had a 27% decrease in risk of leg swelling (edema).
†FU (fibrinolytic units). FU is how manufacturers measure the blood dissolving strength of nattokinase. The higher the FU, the stronger and more effective the product.
††Pine bark extract is a powerful antioxidant shown to promote healthy circulation. The combination and strength of pine bark extra and nattokinase in NattoPine is the only formula studied in a human clinical trial.
‡Results based on a published human clinical trial (Angiology.2003;54(5):531-539).
Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial, by Cesarone MR et al. Angiology. 2003;54(5):531-539. [Article]
Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase, by Sumi, H. et al. Acta haematol 1990, 84: 139-43. [Article]
Article at-a-glance: 70% of Americans take at least one prescription, 50% take two and 20% are on five medications. Drugs cause osteoporosis and can double your risk of bone fracture. Prescriptions are often overlooked as the cause of osteoporosis in up to 30% of...
Article at-a-glance: Fracture a hip with osteoporosis and you have a 20-40% chance of dying in a year. The bone density myth that has people focusing too much on their T-score. Modifiable risk factors are in your control. Change them and change your risk. By Dr. John...
Article at-a-glance: Bone fracture is the most painful and dangerous risk for people with osteoporosis. MK4 and MK7 are both forms of natural vitamin K2. MK4 stops and reverse bone loss, grows stronger bones and reduces fractures up to 87%. MK7 has never been shown to...
Research Citations for Ingredients in NattoPine
Nattokinase and Pine Bark Extract Citations
- Arcangeli P. Pycnogenol in chronic venous insufficiency. Fitoterapia. Jun 2000;71(3):236-244.
- Cesarone MR, Belcaro G, Nicolaides AN, et al. Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial. Angiology. Sep-Oct 2003;54(5):531-539.
- Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids. Oct 2002;37(10):931-934.
- Grimm T, Skrabala R, Chovanova Z, et al. Single and multiple dose pharmacokinetics of maritime pine bark extract (Pycnogenol) after oral administration to healthy volunteers. BMC Clinical Pharmacology. 2006;6(1):4.
- Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res. March 2002;Suppl 1:S1-5.
- Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci. Nov 8 2004;75(21):2505-2513.
- Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res. Sep 2002;16(6):567-571.
- Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med. Sep 1999;27(5-6):704-724.
- Pais E, Alexy T, Holsworth RE, Jr., Meiselman HJ. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. 2006;35(1-2):139-142.
- Petrassi C, Mastromarino A, Spartera C. Pycnogenol in chronic venous insufficiency. Phytomedicine. Oct 2000;7(5):383-388.
- Rimbach G, Virgili F, Park YC, Packer L. Effect of procyanidins from Pinus maritima on glutathione levels in endothelial cells challenged by 3-morpholinosydnonimine or activated macrophages. Redox Rep. 1999;4(4):171-177.
- Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. Apr 2002;40(4):158-168.
- Tai M-W, Sweet BV. Nattokinase for prevention of thrombosis. Am J Health Syst Pharm. 2006;63(12):1121-1123.
- Urano T, Ihara H, Umemura K, et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem. Jul 6 2001;276(27):24690-24696.
- Young Gon Kim HYP. The effects of Pycnogenol on DNA damage in vitro and expression of superoxide dismutase and HP1 in Escherichia coli SOD and catalase deficient mutant cells. Phytotherapy Research. 2004;18(11):900-905.
Your purchases help us support these charities and organizations:
Disclaimer: These statements have not been evaluated by the FDA.
These products are not intended to diagnose, treat, cure, or prevent any disease.